Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enavogliflozin + gemigliptin + metformin
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Enavogliflozin + gemigliptin + metformin is a triple combination therapy being developed by Daewoong Pharmaceutical for the treatment of type 2 diabetes mellitus. The combination consists of enavogliflozin (DWP16001), a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor that promotes urinary glucose excretion; gemigliptin (DWC202204), a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to enhance insulin secretion; and metformin (DWC202205), a biguanide that reduces hepatic glucose production and improves insulin sensitivity. This combination is designed to provide intensive glycemic control in patients who have insufficient blood sugar control with dual therapy or standard-of-care treatments.
- Other names
- Enavogliflozin + Gemigliptin + Metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SGLT2 (Sodium-glucose cotransporter protein subunit 2)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on enavogliflozin + gemigliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enavogliflozin + gemigliptin + metformin.